DRGEM Q1 Net Profit Surges 245% YoY to 3,982M Won

Revenue W27,328M (+17.1%), OP W2,738M, Net profit W3,982M (+245% YoY)
EPS W365 (vs W106 in Q1 2025), significant increase
Capital surplus of W6.8B transferred to retained earnings (board resolution Feb 4, 2026) → boosts dividend capacity
Dividend policy: 15~30% of consolidated net profit for 2026~2028
Sound financials: adj. debt ratio 18%, cash & equivalents W17.1B, net borrowings W10B (long-term)
R&D spending W2.06B (7.53% of sales), new products PROMO & RAYMO commercialized
Export ratio 89.7%, key certifications (MDR, Health Canada) secured
Related party transactions: sales to Medigem W2.58B, purchases from Lusem W1.11B
Auditor changed from Samwha to Samil (periodic designation)